InnoCare Pharma (HKSE:09969) Land And Improvements : HK$0.0 Mil (As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is InnoCare Pharma Land And Improvements?

InnoCare Pharma's land and improvements for the quarter that ended in Jun. 2024 was HK$0.0 Mil.

InnoCare Pharma's quarterly land and improvements declined from Dec. 2023 (HK$248.3 Mil) to Mar. 2024 (HK$0.0 Mil) but then stayed the same from Mar. 2024 (HK$0.0 Mil) to Jun. 2024 (HK$0.0 Mil).

InnoCare Pharma's annual land and improvements increased from Dec. 2021 (HK$89.7 Mil) to Dec. 2022 (HK$258.9 Mil) but then declined from Dec. 2022 (HK$258.9 Mil) to Dec. 2023 (HK$248.3 Mil).

InnoCare Pharma Land And Improvements Historical Data

The historical data trend for InnoCare Pharma's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InnoCare Pharma Land And Improvements Chart

InnoCare Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Land And Improvements

Get a 7-Day Free Trial

89.73

258.90

248.32

InnoCare Pharma Quarterly Data
	Dec17	Sep18	Dec18	Jun19	Sep19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Land And Improvements	Get a 7-Day Free Trial															-	248.32	-	-	-

InnoCare Pharma Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.

InnoCare Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InnoCare Pharma Ltd (HKSE:09969) » Definitions » Land And Improvements

Comparable Companies

Traded in Other Exchanges

33C:Germany 688428:China

Address

No. 8 Life Science Park Road, Building 8, Zhongguancun Life Science Park, Changping District, Beijing, CHN, 102206

Website

https://www.innocarepharma.com

InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.

Executives

The Goldman Sachs Group, Inc.	2201 Interest of corporation controlled by you
Cui Jisong
King Bridge Investments Limited	2101 Beneficial owner
Pang Kee Chan Hebert	2201 Interest of corporation controlled by you
Shi Yigong
Zhao Renbin
Sunny View Holdings Limited
Gic Special Investments Private Limited	2102 Investment manager
Gic Private Limited	2201 Interest of corporation controlled by you
Gic (ventures) Pte. Ltd.	2201 Interest of corporation controlled by you
Hhlr Fund, L.p.	2101 Beneficial owner
Highbury Investment Pte Ltd	2201 Interest of corporation controlled by you
Hhlr Advisors, Ltd.	2102 Investment manager
Tmf (cayman) Ltd.	2301 Trustee
Sunland Biomed Ltd	2101 Beneficial owner

InnoCare Pharma Headlines

No Headlines